Phase 3 Readout~month

Phase 3 Topline: A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-257

Indication
Higher-risk Myelodysplastic Syndrome

Other upcoming events for AAPG

Phase 3 ReadoutPhase 3 Topline: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575)
Phase 3 ReadoutPhase 3 Topline: A Global, Multicenter, Randomized, Double-blind, Phase 3 Pivotal Registrational Clinical Study of AP
Phase 3 ReadoutPhase 3 Topline: A Pivotal Registrational Phase 3 Study of Olverembatinib Combined With Chemotherapy Versus Investiga
Patent ExpiryPatent/Exclusivity Expiry: BOSULIF

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Global Multicenter, Double-blind, Randomized, Registrational Phase 3 Study of Lisaftoclax (APG-257 — AAPG Phase 3 Readout | BioSniper